AstraZeneca’s strong Q3 results and $1.5 bn restructuring plan lift FTSE 100 to first monthly gain in three months

AstraZeneca reported third‑quarter revenue of $16,209 million, up 7 % at constant exchange rates, and core earnings per share of $2.79, up 19 % at constant exchange rates. The drugmaker also announced a restructuring programme expected to save about $1.5 billion and reaffirmed its full‑year guidance. The upbeat results and cost‑saving plan drove AstraZeneca shares sharply higher, helping the FTSE 100 close at 10,729.78 – its first monthly gain in three months.

The share‑price rally in AstraZeneca, the index’s largest component, contributed the bulk of the FTSE 100’s gain, offsetting losses in banks such as NatWest. Investors in UK equities and index‑linked products may see short‑term upside from the pharma‑driven bounce.

  • 1AstraZeneca’s third‑quarter revenue was $16,209 million, up 7 % at constant exchange rates.
  • 2AstraZeneca’s core earnings per share were $2.79, up 19 % at constant exchange rates.
  • 3The restructuring programme is expected to save around $1.5 billion.
  • 4AstraZeneca reaffirmed its full‑year guidance.
  • 5The FTSE 100 closed at 10,729.78, up 0.07 % from the previous close.
  • 6NatWest Group shares fell about 9 % after its third‑quarter net interest income missed expectations.
  • Materials report different percentage moves for AstraZeneca shares.

Sources